Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups Study Comparing the Fully Human Monoclonal Anti-TNFa Antibody Adalimumab Given Every Second Week With Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in Patients With Early Rheumatiod Arthritis (PREMIER).

Trial Profile

A Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups Study Comparing the Fully Human Monoclonal Anti-TNFa Antibody Adalimumab Given Every Second Week With Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in Patients With Early Rheumatiod Arthritis (PREMIER).

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms PREMIER
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 Aug 2018 Results of a post-hoc analysis of OPTIMA and PREMIER studies assessing predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate, published in the Annals of the Rheumatic Diseases
    • 16 Jun 2018 Results comparing pain and HAQ-DI from RA-BEGIN, PREMIER, ORAL-START, AMBITION and FUNCTION studies were presented at the 19th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top